← Back to headlines
Travere Inks Licensing Deal Worth Up to $1.1B with China’s Everest Medicines
Travere Therapeutics has signed a licensing agreement with China's Everest Medicines, a deal potentially valued at up to $1.1 billion.
2 Jun, 12:07 — 2 Jun, 12:07
Sources
Showing 1 of 1 sources
Related Stories
Aon Agrees to $17 Billion Acquisition of Rival USI Insurance
34m ago
Glacier Bancorp Appoints Byron Pollan as New Chief Financial Officer
42m ago
Prediction Platform Kalshi Bans Former Congressman George Santos for Life
59m ago
U.S. Treasury Yields Surge as Fed Official Signals Support for Rate Hike
1h ago